Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Celgene

5 clinical trials · 5 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Celgene

RECRUITINGPhase 3NCT06911502

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's...

The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's...

Sponsor: CelgeneEnrolling: 40020 locations
Follicular Lymphoma
RECRUITINGPhase 1 / Phase 2NCT06988488

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide...

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory...

Sponsor: CelgeneEnrolling: 6220 locations
Multiple Myeloma
RECRUITINGPhase 3NCT05519085

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and...

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone...

Sponsor: CelgeneEnrolling: 81020 locations
Relapsed or Refractory Multiple Myeloma
RECRUITINGPhase 2NCT06782490

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis...

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

Sponsor: CelgeneEnrolling: 20020 locations
Multiple Sclerosis Spasticity
RECRUITINGPhase 3NCT06764485

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants...

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant...

Sponsor: CelgeneEnrolling: 96020 locations
Metastatic Castration-resistant Prostate Cancer